FibroGen (FGEN) Projected to Post Earnings on Monday

FibroGen (NASDAQ:FGEN) is anticipated to release its earnings data before the market opens on Monday, February 24th. Analysts expect FibroGen to post earnings of ($0.14) per share and revenue of $24.91 million for the quarter.

FibroGen Trading Down 8.6 %

Shares of FGEN opened at $0.71 on Friday. The firm has a market capitalization of $71.13 million, a P/E ratio of -0.57 and a beta of 0.75. The stock’s fifty day simple moving average is $0.53 and its 200 day simple moving average is $0.43. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80.

Analysts Set New Price Targets

Several research analysts recently weighed in on FGEN shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research report on Thursday. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. Finally, StockNews.com started coverage on FibroGen in a research report on Friday. They issued a “hold” rating on the stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.